46 results about "Polyoma virus" patented technology

A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, alone or in combination with low levels of light or other drugs, to selectively inactivate or inhibit hepatitis infection, has been developed. Clinical trial results demonstrate efficacy in a human clinical trial for treatment of hepatitis C by oral administration of methylene blue immediate release formulation, in a dosage of 65 mg twice daily, over a period of at least 100 days. A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, along or in combination with low levels of light or other drugs, to prevent or decrease reactivation of viruses, is also described. The preferred class of patient is infected with, or has been exposed to, viruses such as Herpes simplex virus type 1 & 2, Varicella zoster virus, Epstein-Barr virus, Cytomegalovirus, and Herpes virus type 6 & 7, Adenovirus, and Human polyoma viruses, e.g. JC virus and BK virus. In one embodiment the thiazine dye is administered to a patient experiencing symptoms or disease caused by reactivation of a virus. In a preferred embodiment the thiazine dye is administered to a patient at risk for or experiencing symptoms or disease caused by reactivation of a virus, prior to or during immunosuppression or chemotherapy.

RNA interference using small interfering RNAs which are specific for mRNA produced from the JCV agnoprotein and large T antigen genes inhibits expression of these and other primate polyomavirus genes. Primate polyomavirus infection, and diseases which are associated with primate polyomavirus infection, can be treated by administering the small interfering RNAs.

The present invention relates to HLA-A*02-restricted cellular epitopes within the VP1 polypeptide of a human polyomavirus, BK virus, which is associated with polyomavirus-associated nephropathy in kidney transplant patients. Preferred peptides correspond to amino acids residues 107-116, 108-116 and 44-52 of BKV VP1, and are processed in vivo in natural infection with BKV. Effector T cell populations stimulated by the peptides represent functional CTLs as assessed by cytotoxicity and cytokine production, and are reactive against cells presenting both the BKV peptides above and the JC virus homolog sequences.

The present invention relates to PMEA lipid conjugates and to methods of using the conjugates to treat diseases caused by viruses such as herpes, cytomegalovirus, varicella, paramyxovirus, polyoma virus, and human papillomavirus. Methods for making the PMEA lipid conjugates are also provided.

This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).

Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.

The invention provides a multiplex PCR primer set, a kit and a method for simultaneous detection of EHV (Eel herpes virus), JEECV (Japanese eel endothelial cells-infecting virus) and AmPV (Anguilla marmorata polyoma-like virus). According to obtained nucleic acid sequences, specific primers for amplification of EHV, JEECV and AmPV are designed to avoid formation of stable primer dimmers between primers, specificity of primer amplified sequences is analyzed to obtain the primer set that is composed of 6 nucleic acid sequences including SEQ ID NO:1-6 and has high amplification sensitivity and specificity on EHV, JEECV and AmPV simultaneously. The multiplex PCR primer set, kit and method provided by the invention can simultaneously detect and identify EHV, JEECV and AmPV in one PCR reaction system, have the advantages of simple operation and strong specificity, etc., and can directly determine the result according to different amplification lengths, thus being more efficient and practical.

The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

The invention relates to the field of molecular biological detection, in particular to detection of polyoma viruses. The invention provides a composition for detecting and typing the polyoma viruses.Meanwhile, the invention further provides a kit comprising the composition, an application of the composition and a method for detecting and typing the polyoma viruses. The composition disclosed by the invention can be used for simultaneously detecting and typing the three types of viruses in a test by using a tube, and is low in cost, high in flux, short in time, high in sensitivity and good in specificity.

Provided herein is a novel human polyomavirus, its nucleic acid sequence, as well as methods to detect and diagnosis the presence of the polyomavirus.

The present invention includes methods and compositions for elimination of polyomaviruses, such as John Cunningham Virus (JVC), from host cells, and the treatment of polyomavirus related diseases, such as progressive multifocal leukoencephalopathy (PML). The compositions include isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a polyomavirus.

Provided herein is a novel human polyomavirus, its nucleic acid sequence, as well as methods to detect and diagnosis the presence of the polyomavirus.

The present invention relates to the field of disinfectants. Provided in the present invention is a disinfectant composition, which comprises, in percentages by mass: 59-88% of ethanol, 1.5-8% of isopropanol, 0.2-8% of urea, 0.2-6% of an organic acid, 0.1-2% of borneol, 0.1-3% of a zinc salt, and the balance of water. The disinfectant composition provided by the present invention can be applied to the surface disinfection of various inanimate objects, and can also be applied to skin disinfection to effectively play a role in killing Staphylococcus aureus, Escherichia coli, Candida albicans, Pseudomonas aeruginosa, poliovirus, adenoviruses, norovirus, polyomavirus, etc. Strict disinfection requirements are met, and no skin irritation is caused.

Provided is a new polyomavirus, provisionally named MX polyomavirus, (MXPyV). Further provided are cDNA nucleic acid sequences, recombinant proteins, expression vectors and host cells, recombinant anti-MXPyV antibodies, vaccines, compositions, methods of detecting MXPyV, methods for assaying for anti-MXPyV compounds, and methods for treating or preventing a MXPyV infection.

The invention discloses application of diacerein in preparation of antiviral drugs and treatment of virus infection, and belongs to new application of diacerein. The experimental results prove that diacerein can be used for effectively inhibiting hepatophilic DNA viruses, retroviruses, enteroviruses, orthomyxoviruses, fibroviruses, reoviruses, arenavirus, hepatitis E viruses, astroviruses, circoviruses, coronaviruses, parvoviruses, adenoviruses, polyomaviruses, herpes viruses, poxviruses, human papillomaviruses, paramyxoviruses, flaviviruses, herpes viruses, alphaviruses and rhabdoviruses.

The present invention relates to anti-polyomavirus antibodies, antibody fragments, and their uses for the prevention and treatment of BK or JC virus infection and associated diseases.

Provided herein are methods of rapidly expanding BKV-specific T cells using a peptide mixture and cytokines. Further provided herein are methods of treating polyomavirus-associated diseases by administering the BKV-specific T cells.

Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.

The invention provides a novel vaccine for preventing and treating Merkel cell carcinoma. According to the novel vaccine for preventing and treating Merkel cell carcinoma, nucleotide sequences, such as SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4, having 71.9%-74.7% homology with SEQ ID No.6 are cloned and expressed, and the vaccine based on the Merkel cell carcinoma polyoma virus capsid protein VP1 is constructed. The problems of prevention and treatment of Merkel cell carcinoma are effectively solved, and great application value and application prospects are achieved.

The invention relates to a primer and a probe for real-time fluorescence quantification PCR detection of goose polyoma virus and belongs to the field of epizootiology. The invention includes design for specific primer and probe sequence, construction for standard plasmid, establishment for real-time fluorescence quantification PCR amplification method, condition optimization, detection result judgment and application. The method for real-time fluorescence quantification PCR detection of goose polyoma virus established by the invention has high sensitivity, high stability, high specificity and high repeatability for detecting the goose polyoma virus, can be used for detecting at least 35.4 copies and can be used for detecting the infection of the goose polyoma virus in a clinic sample.

The present invention relates to HLA-A*02-restricted cellular epitopes within the VP1 polypeptide of a human polyomavirus, BK virus, which is associated with polyomavirus-associated nephropathy in kidney transplant patients. Preferred peptides correspond to amino acids residues 107-116, 108-116 and 44-52 of BKV VP1, and are processed in vivo in natural infection with BKV. Effector T cell populations stimulated by the peptides represent functional CTLs as assessed by cytotoxicity and cytokine production, and are reactive against cells presenting both the BKV peptides above and the JC virus homolog sequences.

The invention relates to VLP derived from human polyoma virus loaded with a drug (cargo) as a drug delivery system for transporting said drug into the CNS, in particular of living humans.

The invention provides a bird polyoma virus PCR (polymerase chain reaction) diagnostic kit and a detection method thereof. The bird polyoma virus PCR diagnostic kit comprises a lysate, an amplified reaction mixture, a negative control and a positive control, wherein the lysate is prepared from a DNAiso Reagent; the amplified reaction mixture is prepared from sterilized tri-distilled water, PCR buffer, dNTP, an APV-F upstream primer, an APV-R downstream primer and rTaq DNA polymerase; the negative control is the sterilized tri-distilled water; the positive control is bird polyoma virus positiveplasmids. The kit is high in sensitivity, good in specificity, high in stability, and intuitive in result; the detection method is easy to operate, convenient, fast, and capable of greatly reducing the detection time, provides a forceful technological means for clinically controlling bird polyoma virus infection, and particularly has a significance on rapid diagnosis of parrot bird polyoma virusinfection.

The invention relates to the technical field of biological medicines, in particular to an application of an iron chelating agent in preparation of a medicine for treating or preventing polyoma virus infection.

The invention relates to methods for the production of a recombinant protein in a mammalian cell and methods to enhance the production of recombinant proteins in mammalian cells. More in particular, the invention provides a cell for the production of a recombinant protein of interest wherein said cell is permissive to a polyomavirus and wherein said cell comprises the genetic elements A and B wherein A encodes a polyomaviral large T antigen or a functional equivalent thereof and B comprises a gene encoding a protein of interest under the functional control of a polyomaviral origin of replication or a functional equivalent thereof, wherein said cell lacks the capability to express a polyomaviral small T antigen or a functional equivalent thereof as well as the capability to express a polyomavirus capsid protein.

The present invention provides a method for restoring immune tolerance in vivo. The invention relates to the use of a recombinant gene encoding auto-antigens or parts thereof for restoring immune tolerance to the auto-antigens in vivo, under transcriptional control of polyomaviral early and late promoters. In a preferred embodiment, the invention relates to the use of recombinant polyomaviral gene delivery vector particles, such as simian virus 40 (SV40) viral vector particles encoding one or multiple auto-antigens or parts thereof under transcriptional control of the SV40 early and late promoter, for restoring immune tolerance to the auto-antigens in vivo. The invention also relates to compositions comprising recombinant genes or polyomaviral vectors and uses thereof as treatment for degenerative or dystrophic diseases.

The invention discloses a method for detecting JC polyoma virus through real-time fluorescent quantitative PCR (Polymerase Chain Reaction), provides a group of forward primers, reverse primers and probes for detecting JC virus in a biological product through real-time fluorescent quantitative PCR, and provides a PCR program for carrying out fluorescent quantitative PCR detection by utilizing the forward and reverse primers and the probes. The detection method provided by the invention can be used for detecting all JC viruses of different genotypes, is good in specificity, high in sensitivity and high in variant coverage, and compared with common virus cell culture detection, the detection time is greatly shortened, the labor and material cost is saved, and the detection method is suitable for complex detection of large-batch production of biological products.

Provided herein are methods of rapidly expanding BKV-specific T cells using a peptide mixture and cytokines. Further provided herein are methods of treating polyomavirus-associated diseases by administering the BKV-specific T cells.

The present invention includes methods and compositions for the elimination of polyomaviruses, such as John Cunningham virus (JCV), from host cells, and the treatment of polyomavirus-associated diseases, such as progressive multifocal leukoencephalopathy (PML). The composition comprises an isolated nucleic acid sequence comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a polyomavirus.

The invention discloses a marker for predicting the range and depth of kidney infection of polyoma virus and application thereof. Experiments verify that the combined detection of 58K Golgi protein and polyoma virus specific antigen has important application value in predicting the range and depth of transplanted kidney infection and prognosis of kidney transplantation patients, and is helpful forrisk stratification of infection and adoption of appropriate treatment strategies. The sample adopted by the detection strategy of the invention is urine sediment cells, which can be realized by non-invasive means, and the operation is simple, and most of the processes can be automated and almost can be carried out in each transplantation center.